Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

VA/DoD Clinical Practice Guidelines

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

FDAWarning

Recommendation Against Continued Use: March 28, 2012 – Citalopram Hydrobromide (CELEXA®): new changes have been made to the citalopram product label, specifically: ECG and/or electrolyte monitoring should be performed in patients prescribed citalopram who have relative contraindications to citalopram use, such as in those with comorbid conditions predisposing a risk of QT prolongation; Previous label recommendations that “contraindicated” citalopram use in patients with congenital QT syndrome because of the risk for QT prolongation have been changed to less stringent terminology of “not recommended” to recognize patients with this condition who could benefit from citalopram or who cannot tolerate other alternatives; The maximum dose of citalopram remains at 20mg/day for patients greater than the age of 60 years; Citalopram should be discontinued in patients with QTc measurements persistently above 500ms.
Link to Citalopram Notice